Repare – Talk Bio

Repare axes 75% of staff as it hunkers down on two early stage assets

Repare, 75%

Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes

3 months ago talkbio0Tagged camonsertib, cancer combo trial, cost-effective clinical trials, lunresertib, Malignant neoplasm of endometrium, MYTHIC, Phase 3 trial, Platinum-Resistant Ovarian Carcinoma, Repare

Repare Therapeutics, Phase 3 trial, cancer combo trial, MYTHIC trial, lunresertib, camonsertib, endometrial cancer, platinum-resistant ovarian cancer, cost-effective clinical trials

Repare Therapeutics Cuts 25% of Workforce, Preclinical Team Most Affected

8 months ago talkbio0Tagged Industry, preclinical team, Prioritization, R&D, Repare

Repare Therapeutics, layoffs, preclinical team, R&D prioritization, biotech industry

Repare Backer Amplitude Ventures Launches $192M Biotech Fund for Development and Growth

11 months ago talkbio0Tagged Amplitude, biotech fund, Biotechnology, development aspects, Growth, Investments, Repare, Ventures

Amplitude Ventures, biotech fund, Repare Therapeutics, development, growth, investment, biotechnology